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HLA-G: expression in human keratinocytes 
in vitro and in human skin in vivo* 
Classical, polymorphic major histocompatibility complex class I molecules are 
expressed on most nucleated cells.They present peptides at the cell surface and, 
thus, enable the immune system to scan peptides for their antigenicity. The 
function of the other, nonclassical class I molecules in man is controversial. 
HLA-G which has been shown by transfection experiments to be expressed at the 
cell surface, is only transcribed in placental tissue and in the fetal eye.Therefore, a 
role of HLA-G in the control of rejection of the allogeneic fetus has been 
discussed. We found that HLA-G expression is induced in keratinocytes by 
culture in vitro. Three different alternative splicing products of HLA-G can be 
detected: a full length transcript, an mRNA lacking exon 3 and a transcript devoid 
of exon 3 and 4. Reverse transcription followed by polymerase chain reaction also 
revealed the presence of HLA-G mRNA in vivo in biopsies of either diseased or 
healthy skin. 
1 Introduction 
The human major histocompatibility complex, the HLA 
complex, contains three so-called classical, polymorphic 
class I loci coding for ubiquitously expressed cell surface 
molecules which regulate self/nonself recognition by the 
immune system, since they bind selected peptides from the 
cytoplasm and “present” them at the cell surface for 
inspection by T lymphocytes [l]. Three additional loci 
(class Ib) coding for invariant HLA class I heavy chains 
have been characterized [2]. Whether these molecules have 
a function in immune recognition is controversial. Certain 
mouse class Ib molecules, however, have been shown to 
bind and “present” bacterial or heat-shock protein-derived 
peptides to cytotoxic T lymphocytes [3-51. Recently, a 
non-HLA-encoded class I molecule, CDlb, has been 
demonstrated to restrict the response of human CD4-8- ap 
TCR+ T cells for Mycobacteriurn tuberculosis [6]. In con- 
trast to the classical loci, the transcription of the class Ib 
genes is often restricted to few tissues, supporting a 
specialized function of these molecules. 
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Due to its developmentally regulated expression, the 
HLA-G gene [7-91 is unique among the class I gene family. 
Abundant transcript is only present in cytotrophoblast cells 
of the placenta [lo, 111, although low amounts of HLA-G 
mRNA were also detected in fetal eye [9], fetal liver [12], 
thymus [13] and sperm [14]. Moreover, extensive alterna- 
tive splicing of the HLA-G primary transcript leading to the 
synthesis of three different a chains has been reported [15]. 
In contrast to the full length polypeptide, two isoforms 
lacking either the a2 domain or both the a2 and a3 domains 
were detected. Such isoforms should be incapable of 
binding peptides and 132 microglobulin. Nothing is known 
about the developmental regulation of the production of 
alternative forms to date. 
2 Materials and methods 
2.1 Preparation and cultivation of keratinocytes 
Split-thickness skin was washed several times in PBS 
pH 7.3, then cut into 0.5 x 2 cm pieces and incubated for 
90 min at 37°C in 0.5 % trypsin type XI (Sigma Chemie 
GmbH, Deisenhofen, FRG). The epidermis was peeled off 
and vigorously agitated in RPMI 1640 (Biochrom, Berlin, 
FRG) containing 10% FCS (Biochrom) and 0.01 % 
DNase I (Sigma). The resulting cell suspension was filtered 
through sterile gauze and washed twice in supplemented 
RPMI 1640. The viability of these epidermal cells was 
2 90 % , as determined by trypan blue exclusion. Cells were 
either immediately lysed (freshly isolated keratinocytes; 
fKC) or subjected to further culture (cultured keratino- 
cytes; cKC). For this purpose, single-cell suspensions were 
resuspended in supplemented RPMI 1640 and incubated 
overnight at 37°C and 5 % COz in culture flasks either 
coated or not with collagen G (Biochrom). After incuba- 
tion, nonadherent cells were removed and adherent cells 
cultured for 14 days until confluence in DMEM (Flow 
Laboratories) supplemented with 10 % FCS, 25 mM Hepes- 
buffer (both Biochrom), 1 % antibiotics/antimycotics, 
2 mM L-glutamhe, 5 mM sodium pyruvate, and 1 % nones- 
sential amino acids (aa) (all Gibco BRL, Eggenstein, 
FRG). 
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2.2 Human cell lines and stimulation 
The B-LCL LG2 (HLA-type:-A2, -B27, -Cwl) and the 
choriocarcinoma cell line Jeg-3 were cultured in RPMI 1640 
supplemented with 10 % FCS, 2 mM L-glutamine, and 1 % 
penicillin/streptomycin (all Gibco BRL). Culturing and 
stimulation with IFN-y of the epidermoid carcinoma cell 
line A-431 or of keratinocytes kept without collagen layer 
has been described elsewhere [ 161. 
2.3 Northern blot analysis 
RNA from human placenta, cell lines, and keratinocytes 
was prepared according to the procedure of Chirgwin et al. 
[17]. Ten micrograms of total RNA was separated on 
formaldehyde agarose gels and transferred to Hybond-N+ 
membrane (Amersham Buchler, Braunschweig, FRG) in 
0.05 N NaOH for 2 h according to manufacturer's recom- 
mendation. The filters were sequentially hybridized with 
the following probes: the antisense oligomer P3 (5'- 
CTC CTT TGT TCA GCC ACA TTG GCC-3', exon 3, 
aa 149-157) and the antisense oligomer P3'UT [5'- 
GGG CTG GTC TCT GCA CAA AGA GA-3', 3' un- 
translated region (3'UT)] both specific for HLA-G; the 
antisense oligomer o-LG2-C1 specific for HLA-E [18]; a 
3'UT 550 bp HLA-A-specific probe [18]; a 3'UT 450 bp 
HLA-B-specific probe [18]; and finally a cytokeratin 
K5-specific 581 bp probe containing 95 bp of 5'UTand the 
sequence coding for the first 165 aa amplified from cDNA 
with the oligomers K5-11a (5'-AGA GCC ACC TTC TGC 
GTC CTG C-3') and K5-llb (5'-CTG GAT GCT GGG 
GTC GAT TTG C-3') [19]. Oligonucleotides were labeled 
with terminal deoxynucleotidyl transferase (Boehringer 
Mannheim, Mannheim, FRG) and [a-32P] dATP (Amer- 
sham) [20]. Purification, hybridization, and washing at 
65°C were performed as described [18,21]. Probes were 
labeled by the random primer method 1221 with [a- 
32P] dATP (Amersham). Hybridization and washing at 
65 "C were done as described [23]. 
2.4 Reverse transcriptase (RT)-PCR analysis of cultured 
cells 
For first strand cDNA synthesis, 1 pg of total RNA was 
denatured 3 rnin at 94 "C in 5 pl of 50 mM Tris-HCI pH 8.3, 
75 mM KCI, 3 mM MgC12,lO mM dithiothreitol plus 100 ng 
of either HLA-G-specific oligomer P3'UT or a pan HLA 
class I antisense oligomer P4 (5'-GCC AGG TCA GTG 
TGA TCT CCG C-3', exon 4, aa 211-218 [24]). After an 
annealing step for 10 rnin at 55 "C, the reaction volume was 
raised to 10 pl with the same buffer plus 0.5 mM dNTP, and 
200 U of Moloney murine leukemia virus reverse transcrip- 
tase (Gibco), and cDNA synthesis was carried out for 
60 min at 37 "C. Each cDNA sample was diluted 1/3 and 1 p1 
was amplified in 20 pl PCR buffer (50 mM KCl, 10 mM 
Tris-HC1 pH 8.3, 1 mM MgClZ), 200 pM dNTP, 1.25 U Taq 
polymerase (Boehringer) and 12.5 ng of each amplification 
primer [25].The following primer combinations and amplif- 
ication protocols, run on a PCR Thermal Reactor (Hybaid, 
Teddington, GB) were used: P2-P4: 5 rnin 94 "C, 40 cycles: 
1 min 94 "C, 1 rnin 62 "C, 2 min 72 "C; 10 rnin 72 "C; P2 (5 ' -  
exon 2, aa 59-67)-P3 and P2-P6/3'UT (5'-CAG CTG T I T  
TTG GGA AGA GGA GAC ACG GAA CAC-3', 
CAC ATT GCA GCCTG-3', exon 6 3'UTsplice junction of 
HLA-G): 5 rnin 94 "C; 40 cycles: 1 rnin 94 "C, 1 rnin 55 "C, 
1 min 72°C; 10 rnin 72°C. PCR products were analyzed 
either on 1.2 % agarose gels containing ethidium bromide 
or on 5 % nondenaturing polyacrylamide gels stained with 
ethidium bromide after the run. 
2.5 RT-PCR analysis of skin biopsies 
Skin biopsies, 5 mm in diameter, were lysed in 4 M guanidi- 
nium thiocyanate using an ultraturrax device (IKA, Stau- 
fen, FRG). Total RNA was isolated by the method of 
Chomczynski 1261. First strand cDNA synthesis of 1 pg of 
total RNA primed with oligo-p(dT)15 (Boehringer) was 
performed as described above with the following modifica- 
tion: initial denaturation was carried out at 65°C and 
annealing temperature was set to 28°C. 
The primers P2 and P3 were used to amplify HLA-G1 from 
2 pl of the diluted cDNA reaction by hot start PCR with 
AmpliWax PCR Gem loo@ (Perkin Elmer, Neuried, FRG) 
according to manufacturers recommendations but tailoring 
the reaction mix to half of the volume.The protocol, run on 
a Prem thermocycler (Lep Scientific, Milton Keynes, GB) 
was: 94"C, 5 min; 40 cycles: 94"C, 1 min; 70"C, 1 min, 
72"C, 1 min and finally 72"C, 10 min. Amplification of 
HLA-E cDNA was performed as described [18]. The PCR 
products were analyzed on 1.5 YO agarose gels containing 
ethidium bromide. 
3 Results 
3.1 Isolation of HLA-G mRNA transcription in human 
keratinocytes in vitro 
During the analysis of various tissues for differential 
expression of HLA class I loci by Northern blot analysis, an 
HLA-G-specific antisense oligomer derived from exon 3 
(P3 see Fig. 2a) was found to give a strong signal with RNA 
preparations of normal human keratinocytes (cKC 3) main- 
tained in culture for 14 days on a collagen matrix (Fig. 1). 
These cultured keratinocytes contained at least twice as 
much HLA-G mRNA as the human trophoblast-derived 
choriocarcinoma cell line Jeg-3 and four times more than 
placenta. The level of HLA-A, -B, and -E-specific tran- 
scripts in these cells was very low, similar to that found in 
placenta and Jeg-3. No HLA-G transcript could be 
detected in RNA of fKC 2 of a different donor. The human 
epidermoid carcinoma cell line, A-431, also did not contain 
a detectable HLA-G-specific transcript. Whereas keratino- 
cyte cultures grown on collagen matrices expressed large 
amounts of HLA-G mRNA, only a weak HLA-G induction 
was observed in subsequent keratinocyte preparations 
isolated from two other skin specimens (cKC 1 and cKC 2) 
and maintained in culture without collagen layer for the 
same time. IFN-y treatment did not result in a significant 
increase of HLA-G mRNA in keratinocytes (cKC 1) or in 
the A-431 cell line, whereas a strong induction of HLA-A, 
-B and -E mRNA was observed. All keratinocyte prepara- 
tions have abundant cytokeratin K5 mRNA, characteristic 
for basal keratinocytes (271. Only a weak K5 mRNA signal 
is present in A-431 cells. The specificity of our HLA-G 
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a HLA-G a2 (long exposure) 
b HLA-G a2 (short exposure) 
C HLA-G 3'UT 
d HLA-A 
e HLA-8 
f HLA-E 
g keratin K5 
1 2  3 4 5 6 7 8 9 10 
h 28 s 
Figure 1 .  Detection of HLA-G mRNA by Northern blot analysis. 
Ten micrograms of total RNA per lane were separated on a 
formaldehyde agarose gel, transferred onto Hybond-N+ and 
probed with: the HLA-G-specific antisense oligomer P3 (long 
exposure) (a); P3 (short exposure) (b); the HLA-G-specific 
antisense oligomer P3'UT (c), a HLA-A-specific probe (d); a 
HLA-B-specific probe (e); HLA-E specific antisense oligomer 
o-LG2-C1 (f): a cytokeratin K5-specific probe (g).The amount of 
RNA loaded is visualized by the ethidium bromide staining of the 
28s rRNA (h). 
a 
L a1 a2 a3 TM Cytl 
9 
AAA HLA-GZ ala3 
signal was confirmed by RT-PCR analysis of total RNA 
from cKC 3, using oligonucleotides derived from exon 2 
(P2) and exon 3 (P3) (Fig. 2a) of HLA class I-specific 
cDNA primed with antisense oligomer P4, subcloning the 
amplified 249-bp fragment and sequence determination of 
three subclones (data not shown). The HLA-G sequences 
found are identical t o  two previously published alleles 
[7-lo]. Detection of HLA-G transcripts by RT-PCR con- 
firmed the results of the Northern blot analyses: cells 
negative by Northern blot analysis remained negative 
(Fig. 2b: A-431 and fKC 2). 
3.2 Alternative splicing of HLA-G in keratinocytes 
Our  original HLA-G-specific probe is an oligonucleotide 
derived from exon 3, detecting the normal full length 
HLA-G mRNA (HLA-G1) coding for the complete heavy 
chain (Fig. 2a). The use of an oligomer derived from the 
3'untranslated region (P3'UT) of HLA-G, which should 
hybridize to  all three HLA-G transcripts, indicates that a 
large fraction of the HLA-G mRNA in keratinocytes is 
present as normally spliced HLA-GI  mRNA. Therefore, 
the lack of a strong HLA-G mRNA induction in prepara- 
tions cKC 1 and cKC 2 cannot be explained by preferential 
alternative splicing of a HLA-G transcript due to allelic 
differences or  culture conditions. 
Since Northern blots did not resolve the three HLA-G 
transcripts, RT-PCR assays were employed to investigate 
the alternatively spliced HLA-G mRNA species (HLA-G2 
lacking exon 3,  and HLA-G3 lacking both exon 3 and 
exon4). No RT-PCR primer combination resulted in a 
clean amplification of all three transcripts simultaneously. 
We, therefore, used different primer sets to detect each 
mRNA form in either oligo(dT)-primed cDNA (data not 
shown) or  HLA-G-specific cDNA primed with the 3 'UT 
oligonucleotide (P3'UT) (Figs. 2 and 3). We found that 
cDNA Primer: P4 
PCR primers: P2, P3 
- 394 
- 344 
HLA-G1 -m - 298 
- 220 
1 2  3 4 5 6 7 8 9 10 
Figure2. (a) Alternative splicing products of HLA-G. Boxes indicate the coding exons 1-6 and the 3'UT. Localization of the 
oligonucleotides used in this study are shown with arrow heads indicating the 5' to 3' orientation. Sense primers are depicted above and 
antisense oligomers below the boxes. P6/3'UT is complementary to the end of exon 6 and the beginning of the 3'UT (exon 6/3'UTsplice 
junction) of the different HLA-G species.The domain structure of the extracellularpart of the various translation products is shown on the 
right. (b) Detection of HLA-G1 by RT-PCR in cultured keratinocytes, placenta and Jeg-3 cells. Primers used for cDNA synthesis and 
amplification are indicated.The primer combination F'2 and P3 amplifies specifically a 294 bp fragment only present in HLA-GI .The PCR 
products were analyzed on a 5 % polyacrylamide gel stained with ethidium bromide. 
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a 
cDNA Primer: - p y ~ ~ -  
PCR primers: -P2, P4- 
-1018 
H U G 1  + - 51 61506 
- 394 
-344 
-298 
HLA-G2 + - 220 
1 2 3 4  
b 
cDNA Primer: -pyu~- 
PCR primers: -P2, P3- -P2, P6/3’UT - 
-5161506 
H L A - G l b  -298 
HLA-G3* -220 
1 2  3 4 5 6 7  
- HLA-G DNA 
+ HLA-G1 mRNA 
- HLA-E mRNA 
1 2 3 4 5 6 7 8 9  
Figure 4. Detection of HLA-G1 (upper panel) and HLA-E (lower 
panel) by RT-PCR in biopsies of human skin. HLA-G1 from 
cDNA primed with oligo dTwas amplified with the primers P2 and 
P3 (upper panel). Amplification products derived from cDNA and 
contaminating genomic DNA are indicated. HLA-E from the 
same cDNAwas amplified as described [ 181 (lower panel). Biopsies 
were obtained from different individuals except for scarring 
alopecia (lane 1) and healthy skin 2 (lane 7) .  Biopsiesfrom healthy 
skin were excised from the back (lane 6) and the buttock (lane 7). 
Oligo (dT)-primed cDNA from cKC3 served as a positive control 
(lane 8). 
keratinocytes express all three HLA-G transcripts. How- 
ever, our results do not allow quantitation since the 
amplification products strongly depended on the RT and 
PCR primers. 
3.3 Expression of HLA-G in human skin 
Since HLA-G1 is the HLA-G isoform most likely to have 
an immunological function, we performed RT-PCR ana- 
lyses with P2 and P3 as amplification primers on biopsies 
obtained from diseased and healthy skin from different 
localizations and individuals to assess HLA-G1 expression 
in vivo. Though HLA-G1 expression was detectable in 
psoriatic lesions, healthy skin of the back (Fig. 4) and 
healthy foreskin (data not shown), it was absent in material 
derived from a scarring alopecia and sound skin of the 
buttock (Fig. 4). Amplification of HLA-E cDNA as a 
control demonstrates that absence of HLA-G1 amplifica- 
tion in some biopsies (Fig. 4, lanes 1 and 7) was not due to 
different efficiency of cDNA synthesis. 
4 Discussion 
Figure 3. Amplification of the isomers of 
HLA-G expressed in cultured keratino- 
cytes, placenta and Jeg-3 cells. Primers 
used for cDNA synthesis and amplifica- 
tion are indicated above each panel. (a) 
Amplification with primers P1 and P4 
results in a 475-bp fragment specific for 
HLA-G1 and a 200-bp amplificate derived 
from HLA-G2. (b) Amplification with P2 
and P6/3’UT detects only a 250-bp frag- 
ment derived from HLA-G3 (right), 
although the presence of HLA-GI is 
shown by amplification with P2 and P3 
(left). The PCR products were analyzed 
on 1.2 % agarose gels containing ethidium 
bromide. 
Previous results indicated that HLA-G transcription is 
restricted to few distinct tissues of the fetus [lo-12, 281, 
thymus [13] and sperm [14]. In the placenta, HLA-G and 
HLA-A,B gene expression seem to be inversely related 
([lo], Fig. 1). Here, we present evidence of HLA-G 
expression in non-fetal tissue in vitro and in vivo. HLA-G 
mRNA could be induced by in vitro culture in all keratino- 
cyte preparations, which also led to an increase in HLA-A 
and B transcripts, but the levels of HLA-G mRNA varied 
dramatically (see the weak signal in cKC 1 and cKC 2 versus 
cKC 3 in Fig. 1). In this experiment keratinocytes express- 
ing high levels of HLA-G (cKC3) were cultured on collagen 
G. It was, thus, intriguing to test whether the extracellular 
matrix might deliver an inductive signal for HLA-G 
expression. This seems not to be a general phenomenon 
since keratinocytes from another donor only demonstrated 
a moderate induction of HLA-G mRNA regardless of 
whether they were grown on collagen G or not (data not 
shown). Since preliminary data demonstrate that HLA-G 
transcription can be induced in cultured keratinocytes by a 
variety of stimuli, differences in culturing conditions other 
than collagen G might account for the observed differences 
in induction. The signals and factors regulating HLA-G 
transcription are not known so far, but our results support 
previous findings that these are unique and possibly 
transient in action. The HLA-G enhancer has a deletion in 
the IFN-responsive element, which could explain its unre- 
sponsiveness to IFN treatment (Fig. 1, [7]). Since two 
HLA-G alleles are expressed in cKC 3 cells, the possibility 
of a high expressing HLA-G variant to explain the high 
amount of specific transcript seems rather unlikely. 
Since HLA-G-specific mAb are not available, we could not 
test the cells for cell-surface expression of a HLA-G 
encoded molecule. In transfectant systems HLA-G, in 
contrast to HLA-E, is readily transported to the cell surface 
indicative of a sufficient pool of endogenous peptides 
capable of binding HLA-G [2]. Therefore, it has to be 
assumed that HLA-G can be expressed on the cell surface 
of keratinocytes in a conformation capable to interact with 
T 1ymphocytes.The function of HLA-G and its isoforms is 
not known so far. Previously, the expression of HLA-G was 
thought to be limited to the cytotrophoblast, and it was 
speculated that the HLA-G molecule might regulate 
maternal/fetal immune recognition or specific non-immu- 
nological functions of the placenta [ll, 281. 
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We could also demonstrate that HLA-G is transcribed in 
human skin in vivo. HLA-G1 expression as detected by 
RT-PCR seemed to be considerably lower in psoriatic skin 
lesions as opposed to one biopsy of normal skin (Fig. 4). 
Two other biopsies from the same individuum either from 
healthy or diseased skin did not have any HLA-G mRNA. 
Testing a larger sample, comprising also biopsies from other 
skin lesions and foreskin material (data not shown) did not 
reveal any obvious association between disease and HLA- 
G l  expression. This might either reflect on the heterogene- 
ity of the cells in a biopsy or their activation status. 
Clarifying whether and which keratinocytes express HLA- 
G in the skin, will help to solve this issue. Furthermore, 
different HLA-G alleles have been described recently [29]. 
We cannot rule out the possibility that they might differ in 
their transcriptional activation by different extracellular 
stimuli. Finally, since the HLA-G transcript can be alter- 
natively spliced, factors regulating splice preferences also 
determine the level of HLA-GI expression. In  conclusion, 
the differential detection of HLA-G mRNA in skin biop- 
sies supports the delicate regulation of HLA-G gene 
expression. Since the function of HLA-G expression in 
trophoblast cells is not known, a possible involvement of 
HLA-G in immune responses of the skin remains specula- 
tive. 
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